Shilajit mitigates chemotherapeutic drug-induced testicular toxicity: Study on testicular germ cell dynamics, steroidogenesis modulation, and Nrf-2/Keap-1 signaling.
Level 5 - mechanism / opinion, no new human data
Animal research (rodent model)
PubMed 39121783 · doi:10.1016/j.jaim.2024.100930
What was done
Male Parkes mice received a single intraperitoneal injection of cyclophosphamide (200 mg/kg body weight) to induce testicular toxicity, followed by daily oral supplementation of Shilajit at doses of 100 or 200 mg/kg body weight for one full spermatogenic cycle. Researchers evaluated testicular histology, germ cell kinetics (spermatogonia-to-spermatid conversion, PCNA expression), Sertoli cell markers (N-cadherin, β-catenin), apoptosis markers (Bax/Bcl-2), steroidogenic enzyme activity (3β-HSD, 17β-HSD), oxidative stress markers (SOD, lipid peroxidation), and Nrf-2/Keap-1 pathway signaling.
What was found
Cyclophosphamide disrupted testicular architecture, impaired steroidogenesis, and induced oxido-apoptotic stress. Shilajit co-treatment preserved testicular histoarchitecture, promoted germ cell proliferation and spermatogenesis, stabilized Sertoli cell junction proteins, normalized the Bax/Bcl-2 ratio, activated 3β-HSD and 17β-HSD, decreased lipid peroxidation, increased SOD activity, upregulated Nrf-2, and downregulated Keap-1. The abstract reports qualitative directions of effect but provides no specific quantitative effect sizes or numerical values.
Why it matters
This study provides mechanistic evidence in a rodent model that Shilajit may counter cyclophosphamide-induced gonadotoxicity via antioxidant and steroidogenic pathways. However, clinical applicability to human chemotherapy patients remains unproven.
Limits
The study was conducted exclusively in a mouse model, and the abstract does not report sample size, quantitative data, or statistical variance. Results cannot be directly extrapolated to human reproductive health or clinical oncology settings without controlled human trials.
Cited by
- supports Shilajit supplementation enhances intratesticular antioxidant activity, reducing local reactive oxygen species and stress to support testosterone production.